Skip to main content
Erschienen in:

05.12.2023 | original article

miR-139-5p mediates TGIF1 to regulate the TGFβ pathway and inhibit growth of esophageal squamous cell carcinoma cells

verfasst von: Xiaowu Fan

Erschienen in: European Surgery | Ausgabe 1-2/2024

Einloggen, um Zugang zu erhalten

Summary

Background

Esophageal squamous cell carcinoma (ESCC) is the most prevalent histological subtype of esophageal cancer. miR-139-5p has been shown to have abnormal expression in ESCC. We intend to probe into the roles of miR-139-5p in ESCC, thus providing references for investigating underlying therapeutic targets.

Methods

miR-139-5p expression in esophageal carcinoma was predicted by the Starbase online website. miR-139-5p expression in human ESCC cell lines (KYSE-150, KYSE-410, KSE-30) and human esophageal epithelial cell line Het1A was determined by reverse transcription quantitative polymerase chain reaction (RT-qPCR). KYSE-150 cells were manipulated with miR-139-5p mimic to upregulate miR-139-5p. Cell colony formation, viability, apoptosis, migration, and invasion were assessed by colony formation assay, CCK‑8, flow cytometry, wound healing test, and Transwell. The targeted binding between miR-139-5p and TGIF1 was predicted on Starbase, Targetscan, and miRDB online websites and verified by Dual-Luciferase assay. Cells were transfected with miR-139-5p mimic and pcDNA3.1 TGIF1. The phosphorylation levels of TGFβ pathway-related proteins Smad2 and Smad3 were assessed by RT-qPCR and western blot.

Results

miR-139-5p was underexpressed in ESCC cells. miR-139-5p overexpression reduced ESCC cell viability, migration, and invasion, and promoted apoptosis. TGIF1 overexpression averted miR-139-5p mimic-inhibited ESCC cell growth. miR-139-5p overexpression decreased the phosphorylation levels of TGFβ pathway-related proteins Smad2 and Smad3, while the phosphorylation levels were increased by additional TGIF1 vector transfection.

Conclusion

miR-139-5p mediates TGIF1 to regulate TGFβ pathway and inhibit ESCC cell growth.
Literatur
1.
Zurück zum Zitat Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–43.CrossRefPubMedPubMedCentral Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–43.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111(9):3132–41.CrossRefPubMedPubMedCentral Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111(9):3132–41.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Baba Y, Yoshida N, Kinoshita K, et al. Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study. Ann Surg. 2018;267(3:478–83.CrossRef Baba Y, Yoshida N, Kinoshita K, et al. Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study. Ann Surg. 2018;267(3:478–83.CrossRef
4.
Zurück zum Zitat Reichenbach ZW, Murray MG, Saxena R, et al. Clinical and translational advances in esophageal squamous cell carcinoma. Adv. Cancer Res. 2019;144:95–135.CrossRef Reichenbach ZW, Murray MG, Saxena R, et al. Clinical and translational advances in esophageal squamous cell carcinoma. Adv. Cancer Res. 2019;144:95–135.CrossRef
5.
Zurück zum Zitat Harada K, Baba Y, Ishimoto T, et al. The role of microRNA in esophageal squamous cell carcinoma. J Gastroenterol. 2016;51(6):520–30.CrossRefPubMed Harada K, Baba Y, Ishimoto T, et al. The role of microRNA in esophageal squamous cell carcinoma. J Gastroenterol. 2016;51(6):520–30.CrossRefPubMed
6.
Zurück zum Zitat Drahos J, Schwameis K, Orzolek LD, et al. MicroRNA Profiles of Barrett’s Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium. Cancer Epidemiol Biomarkers Prev. 2016;25(3):429–37.CrossRefPubMed Drahos J, Schwameis K, Orzolek LD, et al. MicroRNA Profiles of Barrett’s Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium. Cancer Epidemiol Biomarkers Prev. 2016;25(3):429–37.CrossRefPubMed
7.
Zurück zum Zitat Sakai NS, Samia-Aly E, Barbera M, et al. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23(6 Pt B:512–21.CrossRef Sakai NS, Samia-Aly E, Barbera M, et al. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23(6 Pt B:512–21.CrossRef
8.
Zurück zum Zitat Mohammadi E, Aliarab A, Babaei G, et al. MicroRNAs in esophageal squamous cell carcinoma: Application in prognosis, diagnosis, and drug delivery. Pathol Res Pract. 2022;240:154196.CrossRefPubMed Mohammadi E, Aliarab A, Babaei G, et al. MicroRNAs in esophageal squamous cell carcinoma: Application in prognosis, diagnosis, and drug delivery. Pathol Res Pract. 2022;240:154196.CrossRefPubMed
9.
Zurück zum Zitat Zheng LJ, Qu YH, Li SL, et al. The suppressive effects of microRNA-139-5p on proliferation and invasion of esophageal squamous cell carcinoma. Zhonghua Yi Xue Za Zhi. 2021;101(13):956–65.PubMed Zheng LJ, Qu YH, Li SL, et al. The suppressive effects of microRNA-139-5p on proliferation and invasion of esophageal squamous cell carcinoma. Zhonghua Yi Xue Za Zhi. 2021;101(13):956–65.PubMed
10.
Zurück zum Zitat Zhang Y, Zhang Y, Ai B, et al. GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis. Oncogene. 2022;41(6):782–96.CrossRefPubMed Zhang Y, Zhang Y, Ai B, et al. GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis. Oncogene. 2022;41(6):782–96.CrossRefPubMed
11.
Zurück zum Zitat Kong L, Yu Y, Guan H, et al. TGIF1 plays a carcinogenic role in esophageal squamous cell carcinoma through the Wnt/beta-catenin and Akt/mTOR signaling pathways. Int J Mol Med. 2021;47(5). Kong L, Yu Y, Guan H, et al. TGIF1 plays a carcinogenic role in esophageal squamous cell carcinoma through the Wnt/beta-catenin and Akt/mTOR signaling pathways. Int J Mol Med. 2021;47(5).
12.
Zurück zum Zitat Guca E, Sunol D, Ruiz L, et al. TGIF1 homeodomain interacts with Smad MH1 domain and represses TGF-beta signaling. Nucleic Acids Res. 2018;46(17):9220–35.CrossRefPubMedPubMedCentral Guca E, Sunol D, Ruiz L, et al. TGIF1 homeodomain interacts with Smad MH1 domain and represses TGF-beta signaling. Nucleic Acids Res. 2018;46(17):9220–35.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Nishimura T, Tamaoki M, Komatsuzaki R, et al. SIX1 maintains tumor basal cells via transforming growth factor-beta pathway and associates with poor prognosis in esophageal cancer. Cancer Sci. 2017;108(2):216–25.CrossRefPubMedPubMedCentral Nishimura T, Tamaoki M, Komatsuzaki R, et al. SIX1 maintains tumor basal cells via transforming growth factor-beta pathway and associates with poor prognosis in esophageal cancer. Cancer Sci. 2017;108(2):216–25.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Singh V, Singh AP, Sharma I, et al. Epigenetic deregulations of Wnt/beta-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: Outcome of DNA methylation. J Cancer Res Ther. 2019;15(1):192–203.CrossRefPubMed Singh V, Singh AP, Sharma I, et al. Epigenetic deregulations of Wnt/beta-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: Outcome of DNA methylation. J Cancer Res Ther. 2019;15(1):192–203.CrossRefPubMed
15.
Zurück zum Zitat Zhao Y, Zhu J, Shi B, et al. The transcription factor LEF1 promotes tumorigenicity and activates the TGF-beta signaling pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2019;38(1):304.CrossRefPubMedPubMedCentral Zhao Y, Zhu J, Shi B, et al. The transcription factor LEF1 promotes tumorigenicity and activates the TGF-beta signaling pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2019;38(1):304.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ren C, Zhou Z, Wang X, et al. SHCBP1 Promotes the Progression of Esophageal Squamous Cell Carcinoma Via the TGFbeta Pathway. Appl Immunohistochem Mol Morphol. 2021;29(2):136–43.CrossRefPubMed Ren C, Zhou Z, Wang X, et al. SHCBP1 Promotes the Progression of Esophageal Squamous Cell Carcinoma Via the TGFbeta Pathway. Appl Immunohistochem Mol Morphol. 2021;29(2):136–43.CrossRefPubMed
17.
Zurück zum Zitat Wei K, Pan C, Yao G, et al. MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2017;44(4):1545–58.CrossRefPubMed Wei K, Pan C, Yao G, et al. MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2017;44(4):1545–58.CrossRefPubMed
18.
Zurück zum Zitat Yang Y, Zhang Y, Lin Z, et al. Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1. Cancer Cell Int. 2022;22(1):191.CrossRefPubMedPubMedCentral Yang Y, Zhang Y, Lin Z, et al. Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1. Cancer Cell Int. 2022;22(1):191.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Yang F, Sun Z, Wang D, et al. MiR-106b-5p regulates esophageal squamous cell carcinoma progression by binding to HPGD. Bmc Cancer. 2022;22(1):308.CrossRefPubMedPubMedCentral Yang F, Sun Z, Wang D, et al. MiR-106b-5p regulates esophageal squamous cell carcinoma progression by binding to HPGD. Bmc Cancer. 2022;22(1):308.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Yang T, Hui R, Nouws J, et al. Untargeted metabolomics analysis of esophageal squamous cell cancer progression. J Transl Med. 2022;20(1):127.CrossRefPubMedPubMedCentral Yang T, Hui R, Nouws J, et al. Untargeted metabolomics analysis of esophageal squamous cell cancer progression. J Transl Med. 2022;20(1):127.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–14.CrossRefPubMed Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–14.CrossRefPubMed
22.
Zurück zum Zitat Liu R, Yang M, Meng Y, et al. Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. Plos One. 2013;8(10):e77068.CrossRefPubMedPubMedCentral Liu R, Yang M, Meng Y, et al. Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. Plos One. 2013;8(10):e77068.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Wang B, Ma Q, Wang X, et al. TGIF1 overexpression promotes glioma progression and worsens patient prognosis. Cancer Med. 2022;11(24):5113–28.CrossRefPubMedPubMedCentral Wang B, Ma Q, Wang X, et al. TGIF1 overexpression promotes glioma progression and worsens patient prognosis. Cancer Med. 2022;11(24):5113–28.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Li J, Hu M, Liu N, et al. HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFbeta axis. J Exp Clin Cancer Res. 2020;39(1:248.CrossRef Li J, Hu M, Liu N, et al. HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFbeta axis. J Exp Clin Cancer Res. 2020;39(1:248.CrossRef
25.
Zurück zum Zitat Ju Q, Jiang M, Huang W, et al. CtBP2 interacts with TGIF to promote the progression of esophageal squamous cell cancer through the Wnt/beta-catenin pathway. Oncol Rep. 2022;47(2). Ju Q, Jiang M, Huang W, et al. CtBP2 interacts with TGIF to promote the progression of esophageal squamous cell cancer through the Wnt/beta-catenin pathway. Oncol Rep. 2022;47(2).
26.
Zurück zum Zitat Wang JL, Qi Z, Li YH, et al. TGFbeta induced factor homeobox 1 promotes colorectal cancer development through activating Wnt/beta-catenin signaling. Oncotarget. 2017;8(41):70214–25.CrossRefPubMedPubMedCentral Wang JL, Qi Z, Li YH, et al. TGFbeta induced factor homeobox 1 promotes colorectal cancer development through activating Wnt/beta-catenin signaling. Oncotarget. 2017;8(41):70214–25.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Xiang G, Yi Y, Weiwei H, et al. TGIF1 promoted the growth and migration of cancer cells in nonsmall cell lung cancer. Tumour Biol. 2015;36(12):9303–10.CrossRefPubMed Xiang G, Yi Y, Weiwei H, et al. TGIF1 promoted the growth and migration of cancer cells in nonsmall cell lung cancer. Tumour Biol. 2015;36(12):9303–10.CrossRefPubMed
Metadaten
Titel
miR-139-5p mediates TGIF1 to regulate the TGFβ pathway and inhibit growth of esophageal squamous cell carcinoma cells
verfasst von
Xiaowu Fan
Publikationsdatum
05.12.2023
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 1-2/2024
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-023-00818-7

Weitere Artikel der Ausgabe 1-2/2024

European Surgery 1-2/2024 Zur Ausgabe